|
1) Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours (Uicc International Union Against Cancer). Geneva: Wiley-Blackwell. 2009
|
|
|
|
|
2) 日本肺癌学会. 臨床・病理肺癌取扱い規約(抜粋)別冊. 2010
|
|
|
|
|
|
3) Sobin LH, Wittekind C. TNM Classification of Malignant Tumours (UICC). New York: Wiley-Liss. 1997
|
|
|
|
|
|
4) Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997; 111: 1710-7
|
|
|
|
|
5) Sobin LH, Wittekind C. TNM Classification of Malignant Tumours (UICC). New York: Wiley-Liss. 2002
|
|
|
|
|
|
6) Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. New York: Springer. 2009
|
|
|
|
|
|
7) Goya T, Asamura H, Yoshimura H, et al. Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer. 2005; 50: 227-34
|
|
|
|
|
|
8) Rami-Porta R, Ball D, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2007; 2: 593-602
|
|
|
|
|
|
9) Rusch VW, Crowley J, Giroux DJ, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2007; 2: 603-12
|
|
|
|
|
|
10) Rusch VW, Asamura H, Watanabe H, et al. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009; 4: 568-77
|
|
|
|
|
|
11) Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007; 2: 706-14
|
|
|
|
|
|
12) Postmus PE, Brambilla E, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol. 2007; 2: 686-93
|
|
|
|
|
|
13) Vallieres E, Shepherd FA, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2009; 4: 1049-59
|
|
|
|
|
|
14) Heyneman LE, Herndon JE, Goodman PC, et al. Stage distribution in patients with a small (＜ or ＝ 3 cm) primary nonsmall cell lung carcinoma. Implication for lung carcinoma screening. Cancer. 2001; 92: 3051-5
|
|
|
|
|
|
15) Gajra A, Newman N, Gamble GP, et al. Impact of tumor size on survival in stage IA non-small cell lung cancer: a case for subdividing stage IA disease. Lung Cancer. 2003; 42: 51-7
|
|
|
|
|
|
16) Wisnivesky JP, Yankelevitz D, Henschke CI. The effect of tumor size on curability of stage I non-small cell lung cancers. Chest. 2004; 126: 761-5
|
|
|
|
|
|
17) Barbieri V, Tassone P, Tagliaferri P. The IASLC Lung Cancer Staging Project: revision proposal of pleural effusion and controlateral nodule staging. J Thorac Oncol. 2008; 3: 317; author reply 317-8
|
|
|
|
|
|
18) Fukui T, Mori S, Hatooka S, et al. Prognostic evaluation based on a new TNM staging system proposed by the International Association for the Study of Lung Cancer for resected non-small cell lung cancers. J Thorac Cardiovasc Surg. 2008; 136: 1343-8
|
|
|
|
|
|
19) Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg. 1978; 76: 832-39
|
|
|
|
|
|
20) Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest. 1997; 111: 1718-23
|
|
|
|
|
|
21) Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497-500
|
|
|
|
|
|
22) Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-39
|
|
|
|
|
|
23) Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2009; 11: 121-8
|
|
|
|
|